Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<i>In situ</i> exsolving RuFe/La<sub>0.6</sub>Sr<sub>0.4</sub>Fe<sub>0.95</sub>Ru<sub>0.05</sub>O<sub>3-δ</sub> interfaces for direct and ethane-intensified CO<sub>2</sub> electrolysis in solid oxide electrolysis cells.

National science review·2026

Same author

Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.

American journal of clinical pathology·2026

Same author

PAX8 controls proximal tubule epithelial identity and stress response through epigenetic modification of distal regulatory elements.

The Journal of biological chemistry·2026

Same author

Evaluating the Performance of Photon- and Electron-Based Fragmentation Methods in Omnitrap-LCMS Analysis of <i>N</i>-Glycopeptides.

Analytical chemistry·2026

Same author

iSCORE-PD: an isogenic stem cell collection to research Parkinson's disease.

Nature communications·2026

Same author

Spatial distribution of the proteome in the human body and in cancers.

Nature·2026

Same journal

Daily briefing: How cooperation built the world.

Nature·2026

Same journal

Deep-sea oddities and boatloads of other new species - June's best science images.

Nature·2026

Same journal

From cloning to gene-editing: the enduring legacy of Dolly the sheep.

Nature·2026

Same journal

Time to give hydration breaks the red card? What science says about keeping cool.

Nature·2026

Same journal

Universities are relying on AI-detection software to catch cheating. How well do the programs work?

Nature·2026

Same journal

Daily briefing: 'Cyborg' cockroaches breathe underwater with printed suit.

Nature·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 9, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Lanbo Xiao^1,2, Abhijit Parolia^1,2,3, Yuanyuan Qiao^1,2,4

¹Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.

|December 23, 2021

Summary

This summary is machine-generated.

A novel PROTAC degrader, AU-15330, targets SWI/SNF ATPase subunits SMARCA2 and SMARCA4. This dual degradation shows promise for treating prostate cancer by disrupting oncogenic gene programs and enhancer accessibility.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

CD Spectroscopy to Study DNA-Protein Interactions

CD Spectroscopy to Study DNA-Protein Interactions

Published on: February 10, 2022

Related Experiment Videos

Last Updated: Oct 9, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

CD Spectroscopy to Study DNA-Protein Interactions

CD Spectroscopy to Study DNA-Protein Interactions

Published on: February 10, 2022

Area of Science:

Oncology
Molecular Biology
Chromatin Biology

Background:

The switch/sucrose non-fermentable (SWI/SNF) complex is vital for chromatin remodeling and frequently altered in cancer.
SMARCA2 and SMARCA4 are ATPase subunits of the SWI/SNF complex implicated in cancer development.

Purpose of the Study:

To develop and evaluate a PROTAC degrader targeting SMARCA2 and SMARCA4.
To investigate the therapeutic potential of dual SWI/SNF ATPase degradation in prostate cancer.

Main Methods:

Development of a PROTAC degrader (AU-15330) targeting SMARCA2 and SMARCA4.
Assessment of sensitivity in prostate cancer cell lines versus normal and other cancer cell lines.
Analysis of cis-regulatory element compaction, transcription factor displacement, and gene program disruption.
Evaluation in prostate cancer xenograft models, including combination therapy with enzalutamide.

Main Results:

AU-15330 selectively degrades SMARCA2 and SMARCA4 in AR+ FOXA1+ prostate cancer cells.
Degradation leads to rapid chromatin compaction, dislodging key transcription factors (AR, FOXA1, ERG, MYC).
AU-15330 inhibits tumor growth, synergizes with enzalutamide, and achieves remission in CRPC models without toxicity.

Conclusions:

Dual SWI/SNF ATPase degradation is a potent strategy against prostate cancer.
Targeting SWI/SNF-mediated enhancer accessibility offers a promising therapeutic avenue for enhancer-addicted cancers.